Plain-English translation of NCT07259252 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This trial is testing whether an influenza vaccination can help prevent serious heart problems—like another heart attack, stroke, or heart-related death—in people who have recently experienced acute coronary syndrome (a sudden heart event). Researchers will compare people who receive the flu vaccine to those who receive a placebo (a dummy shot with no active medicine) to see if the medication reduces the risk of future cardiac complications.
People who have had a recent heart attack face a higher risk of another cardiac event. This research explores whether this medication, which is already available, might offer additional heart protection beyond its standard flu-prevention benefits.
You likely qualify if…
You likely don't qualify if…
After you join the study, you will receive either a flu shot or a placebo injection. You will then receive follow-up phone calls at 1 month, 3 months, 6 months, and 1 year after you leave the hospital to check on your health and see how you are doing. The study involves about 6,620 participants across the research centers.
AI-generated summary from trial data · Jun 5, 2026 · Not medical advice
China
Sponsor
Tongji Hospital
Enrollment target
~6,620 participants
Started
December 2025
Primary completion
March 2029
Age range
18 Years – 80 Years
Last updated on clinicaltrials.gov in January 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Yang Sun
Tongji Hospital
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.